Cargando…
Dapagliflozin: A Review in Type 1 Diabetes
Oral dapagliflozin (Edistride(®), Forxiga(®)) is approved in the EU at a dosage of 5 mg/day as an adjunct to insulin in adults with type 1 diabetes (T1D) and a body mass index (BMI) of ≥ 27 kg/m(2), when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy. As a...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881422/ https://www.ncbi.nlm.nih.gov/pubmed/31664708 http://dx.doi.org/10.1007/s40265-019-01213-x |